title: Diagnosis and therapy for prostate tuberculosis.
abstract: In its 2012 global report on tuberculosis, the World Health Organization estimated that 3-7% (range 2.1-5.2%) of new cases and 20% (range 13-26%) of previously treated cases had multidrug-resistant tuberculosis (defined as tuberculosis caused by Mycobacterium tuberculosis isolates that are resistant to rifampicin and isoniazid). In many countries in Eastern Europe and central Asia, 9-32% of new patients and more than 50% of previously treated patients have multidrug-resistant tuberculosis. Ninety-three patients with suspected prostate tuberculosis were enrolled in this study and all underwent prostate biopsy. This method allowed confirmation of diagnosis in 32 patients (34.4%): 23 by histology, six by culture and five by polymerase chain reaction (PCR) (among them, two also had positive culture). The efficiency of an optimized scheme for the therapy of prostate tuberculosis (the second part of the study) was estimated in 53 patients. The first group (25 patients) was treated with a standard scheme of chemotherapy; the second group (28 prostate tuberculosis patients) received ofloxacin in addition for 2 months during the intensive phase. The phase continuation in both groups was identical, with rifampicin and isoniazid administered for 6 months. Optimization of the standard therapy by additional administration of ofloxacin improved results of the treatment in 33.8% of patients.
authors.affiliation: Novosibirsk Medical University, Okhotskaya 81-a, Novosibirsk, Russian Federation.
authors.forename: Ekaterina
authors.initials: E
authors.lastname: Kulchavenya
authors.affiliation: Novosibirsk Research TB Institute, Novosibirsk, Russian Federation.
authors.forename: Elena
authors.initials: E
authors.lastname: Brizhatyuk
authors.affiliation: Novosibirsk Research TB Institute, Novosibirsk, Russian Federation.
authors.forename: Victor
authors.initials: V
authors.lastname: Khomyakov
keywords: diagnosis; infection; prostate; prostatitis; therapy; tuberculosis; urogenital
references.citation: Minerva Urol Nefrol. 2012 Dec;64(4):273-8
references.pmid: 23288214
references.citation: Indian J Urol. 2008 Jul;24(3):388-91
references.pmid: 19468474
references.citation: Exp Ther Med. 2013 Aug;6(2):503-508
references.pmid: 24137216
references.citation: Cochrane Database Syst Rev. 2013 Aug 12;(8):CD009071
references.pmid: 23934982
references.citation: Korean J Urol. 2011 Jun;52(6):425-7
references.pmid: 21755022
references.citation: World J Urol. 2006 Feb;24(1):74-8
references.pmid: 16429302
references.citation: Urology. 2001 May;57(5):872-7
references.pmid: 11337284
references.citation: Curr Opin Infect Dis. 2014 Feb;27(1):97-101
references.pmid: 24253463